Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Results preview: J&J, the Juggernaut that won’t spill its load

This article was originally published in Scrip

Executive Summary

Johnson & Johnson will kick off the big pharma financial reporting season this week, announcing its results on Tuesday 22 January. The healthcare behemoth is looking increasingly anomalous as a diversified conglomerate following Abbott Laboratories' spin-off of its pharma business, AbbVie, and Pfizer's recent moves to divest or separate diverse elements of its business, selling nutrition to Nestlé and launching an IPO for its animal health business Zoetis.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts